-
Exendin-4 Workflows for Beta Cell Research
2026-09-15
Build reproducible Exendin-4 assays that connect GLP-1 receptor signaling, cAMP production, and glucose-induced insulin secretion. The workflow also shows how to extend beta cell findings into metabolic, neuronal, transplantation, and yeast-expression studies while separating established evidence from practical recommendations.
-
BMS 599626 dihydrochloride: EGFR/HER2 Workflows
2026-09-15
Use BMS 599626 dihydrochloride to connect receptor-proximal EGFR/HER2 signaling measurements with functional proliferation and xenograft study design. The workflow also shows how machine-learning-guided senescence research can inform assay selection without misclassifying growth arrest as selective senolysis.
-
HIDEN–IMP1 Control of Human Endoderm Differentiation
2026-09-14
Lu et al. identify HIDEN as a gene-desert lncRNA that promotes human definitive endoderm differentiation by supporting IMP1-dependent stabilization of FZD5 mRNA and WNT signaling. The study broadens lncRNA biology beyond loci near protein-coding genes and provides a framework for testing RNA-mediated regulation during stem-cell differentiation.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-14
Zhao and colleagues present a standardized whole-blood stimulation protocol that combines immune challenges with targeted metabolic interventions and cytokine measurement. Its main contribution is a practical, cohort-compatible framework for testing how metabolic pathways selectively shape human immune responses while preserving the complexity of whole blood.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO)
2026-09-13
K1008 is a 200X DMSO-based Protease Inhibitor Cocktail for limiting proteolytic degradation during protein extraction and protease-sensitive assays. Its EDTA-free formulation is suited to workflows that must preserve divalent cations, but it should not be used without validation when DMSO, an included inhibitor, or separate metalloprotease inhibition could compromise the experiment.
-
Angiotensin II: Vascular Research Workflows
2026-09-12
Build reproducible hypertension, vascular remodeling, and aneurysm experiments with a defined Angiotensin II peptide workflow. This guide connects practical dosing and handling decisions with orthogonal signaling assays, while clearly separating established cardiovascular applications from kidney-fibrosis mechanisms that remain hypothesis-generating.
-
SIRT1, Mitochondrial Biogenesis, and Prion Toxicity
2026-09-12
A 2024 study identifies SIRT1-dependent PGC-1α–TFAM signaling as a mechanistic link between mitochondrial biogenesis and neuronal injury caused by the prion peptide PrP106–126 in N2a cells. The findings position Resveratrol as a pharmacological probe for this pathway while highlighting the need to distinguish SIRT1-mediated mitochondrial rescue from broader antioxidant or anti-apoptotic effects.
-
Angiotensin II: From Vascular Signals to AAA Insight
2026-09-11
A translational framework for using Angiotensin II to connect GPCR signaling, oxidative stress, vascular remodeling, and abdominal aortic aneurysm models—while interpreting environmental exposure findings with appropriate mechanistic and experimental limits.
-
Tofacitinib Workflow for RA Macrophage Assays
2026-09-11
Build reproducible RA macrophage experiments around Tofacitinib, from DMSO stock preparation and GM-CSF challenge design to STAT5, cytokine, and mitochondrial readouts. The workflow distinguishes pathway inhibition from metabolic rescue and translates recent mechanistic findings into practical controls, dose ranges, and troubleshooting decisions.
-
Rucaparib Workflows for DNA Repair Research
2026-09-10
Rucaparib (AG-014699) provides a practical PARP1 inhibition tool for testing DNA damage persistence, radiation response, and repair-deficient cancer phenotypes. This workflow connects prostate cancer radiosensitization with emerging SmD2–BRCA1/FANC splicing biology in hepatocellular carcinoma.
-
Defined Culture for Human Intestinal Organoids
2026-09-10
Meghan M. Capeling’s dissertation presents a defined, modular culture strategy for human intestinal organoids, including non-adhesive alginate hydrogels and methods for separating epithelial and mesenchymal compartments. The work provides a practical framework for improving experimental control, reproducibility, and physiological interpretation in studies of human intestinal development.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-09-09
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its inhibition with reduced renal fibrosis, epithelial–mesenchymal transition, and inflammation. By evaluating AZ505 and LLY-507 in experimental kidney injury and tubular epithelial-cell models, the work supports SMYD2–Smad3/STAT3 signaling as a mechanistic framework for renal fibrosis research.
-
Tomivosertib: MNK1 Inhibitor Workflow Guide
2026-09-09
Tomivosertib is a selective MNK1/2 inhibitor for connecting eIF4E phosphorylation with tumor growth, angiogenesis, neuronal activity, and metabolic regulation. This practical guide translates its mechanism into cell-based, combination-treatment, endothelial, and exploratory in vivo workflows, with troubleshooting points for reproducible results.
-
Cepharanthine: An Evidence-Weighted Assay Framework
2026-09-08
Cepharanthine is a biscoclaurine alkaloid with evidence spanning DNA damage, cell-cycle arrest, apoptosis, organoid biology, and tumor research. This article presents an evidence-weighted strategy for selecting assays, interpreting cross-model results, and avoiding overstatement in translational studies.
-
Phytol and Assay Design: Lessons from Soft Matter
2026-09-08
Phytol is more than an RXR ligand: its isomeric composition, solvent behavior, metabolism, and GABAergic actions can shape assay interpretation. This article develops a matrix-aware experimental framework inspired by recent polymer self-assembly research.